$DNTH

2 stories mentioning DNTHUpdated 38d ago

Every FINWIRES story that references DNTH, newest first.

Wedbush Adjusts Price Target on Dianthus Therapeutics to $105 From $103, Maintains Outperform Rating

Dianthus Therapeutics (DNTH) has an average rating of buy and mean price target of $127.64, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $87.50, Change: $-2.74, Percent Change: -3.04%

$DNTH

Insider Trading68d ago

Dianthus Therapeutics Insider Sold Shares Worth $738,844, According to a Recent SEC Filing

Ryan Savitz, Executive Vice President, Chief Financial Officer & Chief Business Officer, on April 09, 2026, sold 8,224 shares in Dianthus Therapeutics (DNTH) for $738,844.SEC Filing:https://www.sec.gov/Archives/edgar/data/1690585/000199232426000006/xslF345X05/ownership.xml

$DNTH

Track with the FINWIRES app suite

FolioX

Track DNTH in your portfolio

WheelAI

Analyze DNTH options with the wheel strategy

StockInsider

See market sentiment on DNTH